Hidroferol Hebdomadaire

Hidroferol Hebdomadaire is a weekly oral product that contains the vitamin D analog calcifediol monohydrate. The formulation is supplied without a specified strength, and it is marketed in the European Union. As a source of 25‑hydroxyvitamin D3, it is intended to raise circulating vitamin D levels when taken as directed. The product belongs to the vitamin D supplementation class and is generally administered by mouth.

Hidroferol Hebdomadaire is used in clinical practice to address conditions related to insufficient vitamin D status.

- Treatment of documented vitamin D deficiency in adults. - Prevention of osteomalacia in individuals at risk. - Adjunct therapy for osteoporosis management to support bone health. - Support for patients with malabsorption syndromes that impair vitamin D synthesis. - Seasonal prophylaxis of low vitamin D levels in populations with limited sun exposure.

Adverse reactions to Hidroferol Hebdomadaire are generally mild, but rare serious events have been reported.

Common: - Transient hypercalcemia symptoms such as mild nausea or constipation. - Headache or dizziness. - Mild fatigue. - Skin rash or mild pruritus.

Serious: - Persistent hypercalcemia leading to kidney stones or calcification of soft tissues. - Severe allergic reactions including anaphylaxis. - Acute pancreatitis associated with markedly elevated calcium levels. - Hepatic dysfunction manifested by elevated liver enzymes.

Before initiating Hidroferol Hebdomadaire, certain safety considerations should be reviewed.

- Assess baseline serum 25‑hydroxyvitamin D, calcium, and phosphate levels. - Use caution in patients with a history of hypercalcemia, renal stones, or granulomatous diseases. - Adjust dose or avoid use in severe renal impairment (eGFR <30 mL/min/1.73 m²). - Monitor calcium and renal function periodically during therapy. - Pregnant or breastfeeding women should consult a healthcare professional before use. - Concomitant use with high‑dose vitamin D supplements may increase risk of toxicity.

Hidroferol Hebdomadaire may interact with other medicines that affect calcium balance or vitamin D metabolism.

Avoid: - High‑dose vitamin D or calcium supplements that could cause hypercalcemia. - Thiazide diuretics, which reduce urinary calcium excretion. - Medications that increase vitamin D activation such as anticonvulsants (e.g., phenobarbital, phenytoin). - Sarcoidosis or other granulomatous disorders where endogenous vitamin D production is elevated.

Use with caution: - Bisphosphonates, as combined therapy may affect bone turnover monitoring. - Corticosteroids, which can impair vitamin D metabolism and require dose adjustment. - Loop diuretics, which increase calcium loss and may counteract the drug’s effect. - Antiretroviral agents (e.g., efavirenz) that may lower vitamin D levels.